Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato
California
94949
United States
Tel: 415-483-8800
Fax: 415-483-8810
Website: http://www.ultragenyx.com/careers/
Email: info@ultragenyx.com
About Ultragenyx Pharmaceutical Inc.
Founded in 2010, Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
Where others turn away or take the road well traveled, we run towards the unknown and blaze new trails. We’re working hard to create treatments where none exist, giving new hope to patients with rare genetic diseases. Because you can only make a meaningful impact when your team has big ambitions. Join Ultragenyx and put your passion to work.
ultrafocused
Ultragenyx is dedicated to fostering a workplace environment that keeps our team inspired and provides the vision, resources and support they need to succeed. That includes maintaining a healthy, inclusive company culture where employees feel respected and valued. And providing opportunities for learning, personal growth, and career advancement. At Ultragenyx we push each other to perform at our very best, because we never lose sight of our mission – to make a difference in our patients’ lives.
283 articles with Ultragenyx Pharmaceutical Inc.
-
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease
1/21/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX701, an investigational AAV9 gene therapy being evaluated for the treatment of Wilson Disease
-
Ultragenyx Reports Preliminary 2020 Revenue and 2021 Revenue Guidance for Crysvita in Ultragenyx Territories
1/11/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported preliminary unaudited 2020 Crysvita revenue in Ultragenyx territories and cash and investments at year end 2020 and provided 2021 revenue guidance for Crysvita in Ultragenyx territories.
-
Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies
1/8/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced positive longer-term safety and efficacy data from the first three cohorts of the ongoing Phase 1/2 studies of DTX401, an investigational adeno-associated virus (AAV) gene therapy for Glycogen Storage Disease Type Ia (GSDIa), and DTX301,
-
Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference
1/5/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 12, 2021 at 2:50 pm EST. The live and archived webcast of the presentation wi
-
Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
12/17/2020
Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Mereo BioPharma Group plc (Nasdaq: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced a license and collaboration agreement for setrusumab
-
Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease
12/9/2020
Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to UX701 for the treatment of Wilson disease, a larger rare metabolic disease that affects more than 50,000 people in the developed world.
-
GeneTx and Ultragenyx Announce Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman Syndrome
12/5/2020
Additional data, including EEG findings, support prior initial indications of activity and there were no new adverse events
-
Ultragenyx to Present at Upcoming Healthcare Conferences
11/24/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the following upcoming investor conference
-
Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases
11/9/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare genetic diseases, today announced that it plans to build a new large-scale gene therapy manufacturing facility in Bedford, Massachusetts.
-
Ultragenyx to Present at Upcoming Investor Conferences - Nov 05, 2020
11/5/2020
Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the following upcoming investor conferences:.
-
Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/2/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the closing of its previously announced underwritten public offering of 5,111,110 shares of its common stock,
-
Ultragenyx Announces Proposed Public Offering of Common Stock - Oct 28, 2020
10/28/2020
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced that it has commenced an underwritten public offering of up to $400,000,000 of shares of its common stock.
-
Ultragenyx Announces Pricing of Public Offering of Common Stock - Oct 28, 2020
10/28/2020
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced the pricing of its underwritten public offering of 4,444,444 shares of its common stock at a price to the public of $90.00 per share resulting in gross proceeds of $400 million, before underwriting discounts.
-
Ultragenyx Reports Third Quarter 2020 Financial Results and Corporate Update
10/27/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2020 and updated its full year 2020 guidance
-
GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome
10/26/2020
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced positive interim data from the Phase 1/2 study of GTX-102.
-
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
10/23/2020
Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
-
Ultragenyx to Host Conference Call for Third Quarter 2020 Financial Results and Corporate Update
10/21/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, October 27, 2020 at 5pm ET to discuss third quarter 2020 financial results and provide a corporate update.
-
BioSpace Movers & Shakers, Sept. 4
9/4/2020
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
Ultragenyx to Present at Upcoming Investor Conferences - Sep 03, 2020
9/3/2020
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the following upcoming investor conferences
-
Ultragenyx Appoints Mardi C. Dier as Chief Financial OfficerMs. Dier will start in new role in November 2020
9/2/2020
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it has appointed Mardi C. Dier as Executive Vice President and Chief Financial Officer (CFO), effective November 2, 2020.